Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Cardiology and
1 other channel

Journal Scan / Research · September 30, 2015

Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension

The Lancet

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Ronald Victor MD

The Lancet
PATHWAY-2, a Randomised, Double-Blind, Crossover Trial: Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension
Lancet 2015 Sep 20;[EPub Ahead of Print], B Williams, TM MacDonald, S Morant, DJ Webb, P Sever, G McInnes, I Ford, JK Cruickshank, MJ Caulfield, J Salsbury, I Mackenzie, S Padmanabhan, MJ Brown

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated